Resmed Inc. RMD

NYS: RMD | ISIN: US7611521078   31/08/2026
240,10 USD (-0,10%)
(-0,10%)   31/08/2026

17 augustus 2026 · Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor · Persbericht

21 juli 2026 · BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) · Persbericht

1 juni 2026 · Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio · Persbericht

30 april 2026 · Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor  · Persbericht

3 maart 2026 · Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach · Persbericht

3 september 2025 · Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority · Persbericht

27 augustus 2025 · Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds · Persbericht

21 augustus 2025 · Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs · Persbericht

18 augustus 2025 · Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio · Persbericht

15 mei 2025 · Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 · Persbericht

1 mei 2025 · Resmed Acquires VirtuOx · Persbericht

21 april 2025 · Resmed Names Salli Schwartz as Chief Investor Relations Officer · Persbericht

19 maart 2025 · New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer · Persbericht

11 maart 2025 · Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution · Persbericht

Mijn selecties